IRB #

IRB00002734

Title

A Randomized Phase II Study of Intermittent chemotherapy or Intermittent Chemotherapy with maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer

Principal Investigator

Tomasz Beer

Study Purpose

The purpose of this study is to see what effects GM-CSF, the study drug, has on prostate cancer in subjects who are on an intermittent chemotherapy schedule with docetaxel (Taxotere).

Medical Condition(s)

Prostate Cancer

Eligibility Criteria

* Subjects should have documented prostate cancer that has spread outside the prostate and is no longer responding to hormone therapy.
* Subjects may have up to 3 cycles of prior docetaxel chemotherapy before enrollment
* Subject should not have prior immunotherapy including systemic GM-CSF or vaccines utilizing GM-CSF

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Recruitment End

Compensation Provided

No